Stada Arzneimittel : Stada as she goes
After just one year at the helm of Stada, Claudio Albrecht left on 1Â September to be replaced by Peter Goldschmidt, former head of Novartis' US generics arm Sandoz. Little is known about his intentions as head of Stada but we think that he will essentially follow the same roadmap, focusing on more sophisticated products and cost savings. - Despite some episodes of volatility, bonds have outperformed the high-yield compartment since September's issuance and we believe they will cont...Stada Arzneimittel is engaged in the development and marketing of products with off-patent active pharmaceutical ingredients in the health care and, in particular, in the pharmaceutical market. Generics is based on low pricing and/or a cross-product and cross-indication marketing concept while Branded Products focus on the specific product characteristics and, in particular, on the brand name of individual products. Co.'s business activities are divided into the four market regions of Germany, Central Europe, CIS / Eastern Europe and Asia & Pacific & Middle East / North Africa (MENA).
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.